Citations

Clear

8 citation(s) found for "Sun, Cheng".

Toward autonomous robotic-assisted and microrobotic surgery
Yang, Sungyun , Kang, Byung Ha , Min, Hyeongho , Wachs, Juan , Alambeigi, Farshid , Desai, Jaydev P. , Yaeger, Kurt , Anderson, Katherine, Kuntz, Alan , Alterovitz, Ron , Webster, Robert J. , Hata, Nobuhiko , Reisenauer, Janani , Clinch, McKenna, Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Kim, Peter C., Huang, Alex S. , Zhang, Hao F. , Riviere, Cameron N. , Henderson, Eric R. , Yip, Michael C. , Dong, Xiaoguang , Wollin, Daniel , Mair, Lamar O. , Karpelson, Michael , Wood, Robert J. , Cohen, Itai , Strano, Michael S. , Wachs, Juan P , Dupont, Pierre E , Yaeger, Kurt , Anderson, Katherine , Kuntz, Alan , Alterovitz, Ron , Webster, Robert J , Hata, Nobuhiko , Reisenauer, Janani S , Clinch, McKenna , Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Sun, Cheng , Zhang, Hao F , Riviere, Cameron N , Henderson, Eric R , Yip, Michael , Dong, Xiaoguang , Wollin, Daniel A , Gracias, David H , Mair, Lamar O , Karpelson, Michael , Wood, Robert J , Cohen, Itai , Strano, Michael S

Mayo Clinic

Science Advances | July 1, 2026 | Volume: 12 | Issue: 27 | Pages: No page available

10.1126/sciadv.aec4197 | PMID 42384805 Get It

Autonomous robotic-assisted surgery (RAS) has emerged as a promising objective in biomedical technology, further enhanced by miniaturization toward microrobotic-assisted surgery (μ-RAS). This reduction in scale promises minimally invasive, partially or fully automated surgical procedures, with the potential to reduce patient recovery times, lower medical costs, and enable previously unavailable procedural options. This perspective highlights the specific advances in RAS that potentially map to the microscale (μ-RAS), organized across five surgical domains: endovascular, endoluminal, laparoscopic, ophthalmic, and orthopedic. We examine both clinical demands and technological advances in surgical robotics and identify the key innovations required for progress across these surgical fields. Our contribution is distinct in combining the perspectives of both surgical experts and bioengineering innovators, outlining a roadmap for the advancement and eventual integration of autonomous RAS and μ-RAS into mainstream surgical practice.
l ‐Cysteine Alleviates Peritoneal Fibrosis by Repressing PKM2 in Peritoneal Mesothelial Cells
Ma, Xiaokun , Li, Yin , Huang, Yuebo , Sun, Yuxiang , Sha, Zixin , Lin, Hongchun, Shang, Hongli, Wu, Peizhi, Li, Canming , Ye, Zengchun , Peng, Hui , Peng, Hui , Li, Yongjie, Wei, Dandan, Hu, Cheng , Hu, Zhaoyong

Mayo Clinic

The FASEB Journal | June 11, 2025 | Volume: 39 | Issue: 11 | Pages: No page available

10.1096/fj.202500229r | PMID 40497367 Get It

ABSTRACT Peritoneal fibrosis is one of the main causes of peritoneal dysfunction and withdrawal of patients from peritoneal dialysis (PD). Our previous study has shown that high‐glucose dialysis solution promotes glycolysis in peritoneal mesothelial cells, leading to mesothelial‐to‐mesenchymal transition (MMT) and peritoneal fibrosis. However, the molecular mechanisms remain unclear. Using single‐cell RNA sequencing (scRNA‐seq) analysis of cells from the effluent of patients undergoing PD from our previous study, we found that pyruvate kinase isozymes M2 (PKM2), a key rate‐limiting enzyme of glucose metabolism, was significantly upregulated in the mesothelial cells of patients with long‐term peritoneal dialysis (LPD). Using co‐immunoprecipitation, chromatin immunoprecipitation assay, and gene silencing techniques, we revealed that PKM2 promotes the expression of transcription factor SNAI2 by acetylating histone H3K9 (H3K9ac), thereby promoting the occurrence of MMT and hence peritoneal fibrosis. l ‐cysteine, a known PKM2 inhibitor, blocked these responses and prevented PD‐induced peritoneal fibrosis. These results could provide a novel therapeutic strategy for treating peritoneal fibrosis.
DDDR-10. MYELOID CELLS COORDINATELY INDUCE GLIOMA CELL-INTRINSIC AND -EXTRINSIC PATHWAYS FOR CHEMORESISTANCE VIA GP130 SIGNALING
Cheng, Jiying, Li, Min , Motta, Edyta, Barci, Deivi, Song, Wangyang, Zhou, Ding , Zhu, Sihan, Yang, Anru, Vaillant, Brian, Spiegel-Kreinecker, Sabine, Katayama, Hiroshi , Flüh, Charlotte , Glaß, Rainer , Li, Gen , Imhof, Axel , Forné, Ignasi , Zhang, Nu , Bhat, Krishna , Kälin, Roland E.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii127-viii127

10.1093/neuonc/noae165.0495 Get It

Abstract The DNA damage response (DDR) and the blood tumor barrier (BTB) restrict chemotherapeutic success for primary brain tumors like glioblastoma (GBM). Coherently, GBM almost invariably relapse with fatal outcome. We here show that interaction of GBM and myeloid cells simultaneously induces chemoresistance on the genetic and the vascular level by activating GP130 receptor signaling, which can be addressed therapeutically. We performed transcriptomic and immunohistochemical screens with human brain material, pharmacological experiments with a humanized organotypic GBM model, proteomics and cell-based assays and observed that nanomolar concentrations of the signaling peptide Humanin promoted TMZ resistance through DDR activation. GBM mouse models recapitulating intratumoral Humanin-release showed accelerated BTB formation. Genetic analysis of pericyte to endothelial cell signaling in transgenic mice revealed increased GP130 activation in Humanin releasing tumors as compared to controls. GP130 blockade attenuated both DDR activity and BTB formation resulting in improved preclinical chemotherapeutic efficacy. Altogether, we describe an overarching mechanism for TMZ resistance and outline a translatable strategy with predictive markers to improve chemotherapy for GBM.
Looking Back: International Practice Patterns in Breast Radiation Oncology From a Case-Based Survey Across 54 Countries During the First Surge of the COVID-19 Pandemic
Dunn, Samantha A., Li, Jian , Coles, Charlotte E. , Yamauchi, Chikako , Chang, Jee Suk , Cheng, Skye Hung‐Chun , Meattini, Icro , Ramiah, Duvern , Hijal, Tarek , Poortmans, Philip , Isern, J. , Zissiadis, Yvonne , Offersen, Birgitte Vrou , Hijazi, Hussam, Dengina, Natalia , Belkacémi, Yazid , Luo, Feng, Griffin, Colleen, Collins, Maya, Larios, Dalia, Punglia, Rinaa S. , Wong, Julia S., Spiegel, Daphna Y. , Bellon, Jennifer R. , Ho, Alice Y. , Oladeru, Oluwadamilola T , Yamauchi, Chikako , Chang, Jee Suk , Cheng, Skye Hung-Chun , Kaidar-Person, Orit , Meattini, Icro , Kirby, Anna , Hijal, Tarek , Marta, Gustavo Nader , Isern-Verdum, Josep , Offersen, Birgitte Vrou , Elsayad, Khaled , Lu, Shun , Punglia, Rinaa S , Spiegel, Daphna Y , Jagsi, Reshma , Taghian, Alphonse , Bellon, Jennifer R , Ho, Alice Y , Oladeru, Oluwadamilola T. , Refaat, Tamer , Ryan, Phoebe K. , Warren, Laura Elizabeth , Jagsi, Reshma

Mayo Clinic

JCO Global Oncology | July 20, 2023 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/go.23.00010 | PMID 37471670 Get It

PURPOSE The COVID-19 pandemic has profoundly affected cancer care worldwide, including radiation therapy (RT) for breast cancer (BC), because of risk-based resource allocation. We report the evolution of international breast RT practices during the beginning of the pandemic, focusing on differences in treatment recommendations between countries. MATERIALS AND METHODS Between July and November 2020, a 58-question survey was distributed to radiation oncologists (ROs) through international professional societies. Changes in RT decision making during the first surge of the pandemic were evaluated across six hypothetical scenarios, including the management of ductal carcinoma in situ (DCIS), early-stage, locally advanced, and metastatic BC. The significance of changes in responses before and during the pandemic was examined using chi-square and McNemar-Bowker tests. RESULTS One thousand one hundred three ROs from 54 countries completed the survey. Incomplete responses (254) were excluded from the analysis. Most respondents were from the United States (285), Japan (117), Italy (63), Canada (58), and Brazil (56). Twenty-one percent (230) of respondents reported treating at least one patient with BC who was COVID-19–positive. Approximately 60% of respondents reported no change in treatment recommendation during the pandemic, except for patients with metastatic disease, for which 57.7% (636/1,103; P < .0005) changed their palliative practice. Among respondents who noted a change in their recommendation during the first surge of the pandemic, omitting, delaying, and adopting short-course RT were the most frequent changes, with most transitioning to moderate hypofractionation for DCIS and early-stage BC. CONCLUSION Early in the COVID-19 pandemic, significant changes in global RT practice patterns for BC were introduced. The impact of published results from the FAST FORWARD trial supporting ultrahypofractionation likely confounded the interpretation of the pandemic's independent influence on RT delivery.
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury
Cheng, Jinping , Jiang, Jingru, He, Baixuan, Lin, Wei‐Jye , Li, Yi , Li, Honghong , Huang, Xiaolong , Xie, Jiatian, Zhang, Zhan , Yang, Yuhua , Xu, Yongteng , Hu, Xia , Wu, Minyi, Zhuo, Xiaohuang , Pei, Yu , Rong, Xiaoming , Ye, Xiaojing , Saw, Phei Er , Wu, Long‐Jun , Mai, Hai‐Qiang , Tang, Yamei , Li, Honghong , Zhang, Zhan , Xu, Yongteng , Shi, Zhongshan , Ye, Xiaojing , Saw, Phei Er , Wu, Long-Jun , Simone, Charles B , Chua, Melvin L K , Tang, Yamei , Duan, Jingjing, Cai, Jinhua , Hu, Xia, Liu, Qiang , Yu, Pei, Simone, Charles B. , Chua, Melvin L.K. , Mai, Hai‐Qiang

Mayo Clinic

Science Translational Medicine | February 22, 2023 | Volume: 15 | Issue: 684 | Pages: No page available

10.1126/scitranslmed.abm6543 | PMID 36812346 Get It

Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients with RIBI fail to respond to or have contraindications to the first-line treatments of bevacizumab and corticosteroids. Here, we reported a Simon’s minmax two-stage, single-arm, phase 2 clinical trial (NCT03208413) to assess the efficacy of thalidomide in patients with RIBI who were unresponsive to or had contraindications to bevacizumab and corticosteroid therapies. The trial met its primary endpoint, with 27 of 58 patients enrolled showing ≥25% reduction in the volume of cerebral edema on fluid-attenuated inversion recovery–magnetic resonance imaging (FLAIR-MRI) after treatment (overall response rate, 46.6%; 95% CI, 33.3 to 60.1%). Twenty-five (43.1%) patients demonstrated a clinical improvement based on the Late Effects Normal Tissues–Subjective, Objective, Management, Analytic (LENT/SOMA) scale, and 36 (62.1%) experienced cognitive improvement based on the Montreal Cognitive Assessment (MoCA) scores. In a mouse model of RIBI, thalidomide restored the blood-brain barrier and cerebral perfusion, which were attributed to the functional rescue of pericytes secondary to elevation of platelet-derived growth factor receptor β (PDGFRβ) expression by thalidomide. Our data thus demonstrate the therapeutic potential of thalidomide for the treatment of radiation-induced cerebral vasculature impairment.
Association of early repolarization pattern with cardiovascular outcomes in middle‐aged population: A cohort study
Cheng, Yun‐Jiu , Zhao, Xiaoxiao , Pan, Shun‐Ping, Pan, Jia‐Min, Li, Zhu-yu, Cheng, Yun‐Jiu , Zhang, Ming

Mayo Clinic

Clinical Cardiology | October 26, 2020 | Volume: 43 | Issue: 12 | Pages: 1601-1608

10.1002/clc.23488 | PMID 33103793 Get It

AbstractBackgroundLarge cohort studies provide conflicting evidence regarding the prognostic value of early repolarization pattern (ERP) in the general population, complicated by the complex or heterogeneous definitions of ERP applied in different studies.HypothesisWe hypothesized that ERP was associated with increased cardiovascular risk with the definition of ERP recommended by the expert consensus statements.MethodsA total of 13673 middle‐aged subjects from the prospective, population‐based Atherosclerosis Risk in Communities (ARIC) study were included in this analysis. Cox models were used to estimate the hazard ratios (HRs) adjusted for possible confounding factors. ERP was defined as ST‐segment elevation ≥0.1mV at the end of the QRS or J wave on the QRS downstroke in two or more contiguous leads.ResultsCompared with those without ERP, subjects with ERP had a significantly increased risk of developing sudden cardiac death (SCD) (HR, 1.48; 95% CI, 1.08–2.04) and death from coronary heart disease (CHD) (HR, 1.45; 95% CI, 1.10–1.92) after a median follow‐up of 20.1 years. ERP was significantly predictive of SCD in females, whites, younger people, and subjects with relatively low cardiovascular risk. ERP with ST‐segment elevation appeared to indicate poor cardiovascular outcomes. ERP was associated with an absolute risk increase of 93.3 additional SCDs per 100 000 person‐years.ConclusionsOur findings suggest that ERP was an independent predictor of SCD and CHD death in the middle‐aged biracial population.
Nuclear translocation of AMPK-α1 potentiates striatal neurodegeneration in Huntington’s disease
Ju, Tz‐Chuen , Lin, Jiun‐Tsai, Chang, Ching‐Pang , Chang, Wei-Cheng, Kang, Jheng-Jie, Sun, Cheng‐Pu , Tao, Mi‐Hua , Tu, Pang‐Hsien , Chang, Chen , Dickson, Dennis W. , Chern, Yijuang , Chen, Huimei , Dickson, Dennis W

Mayo Clinic

Journal of Cell Biology | July 18, 2011 | Volume: 194 | Issue: 2 | Pages: 209-227

10.1083/jcb.201105010 | PMID 21768291 Get It

Adenosine monophosphate–activated protein kinase (AMPK) is a major energy sensor that maintains cellular energy homeostasis. Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of CAG repeats in the huntingtin (Htt) gene. In this paper, we report that activation of the α1 isoform of AMPK (AMPK-α1) occurred in striatal neurons of humans and mice with HD. Overactivation of AMPK in the striatum caused brain atrophy, facilitated neuronal loss, and increased formation of Htt aggregates in a transgenic mouse model (R6/2) of HD. Such nuclear accumulation of AMPK-α1 was activity dependent. Prevention of nuclear translocation or inactivation of AMPK-α1 ameliorated cell death and down-regulation of Bcl2 caused by mutant Htt (mHtt). Conversely, enhanced expression of Bcl2 protected striatal cells from the toxicity evoked by mHtt and AMPK overactivation. These data demonstrate that aberrant activation of AMPK-α1 in the nuclei of striatal cells represents a new toxic pathway induced by mHtt.